Use of EMPAgliflozin in the prevention of CARDiotoxicity: the EMPACARD – PILOT trial
Empagliflozin is associated with reduced incidence of CTRCD in high-risk patients treated with anthracyclines. These data should serve as the foundation for a clinical trial to test whether SGLT2 inhibitors can reduce the incidence of heart failure in this patient group.
Authors
- Diego Costa (ORCID: https://orcid.org/0000-0002-8632-1475)
- Teresa López‐Fernández (ORCID: https://orcid.org/0000-0002-3414-7022)
- Andrés J. Daniele
- Vanesa Gregorietti
Institutions
- Hospital La Paz Institute for Health Research (ES)
- Instituto Cardiovascular de Buenos Aires (AR)
Publication Details
- Journal
- Cardio-Oncology
- Published
- 2024-09-05
- DOI
- https://doi.org/10.1186/s40959-024-00260-y
- Citations
- 29
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 10.02